This is a computer translation of the original webpage. It is provided for general information only and should not be regarded as complete nor accurate. Close Disclaimer
Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

The Food and Drug Administration Computed Prescription Drug User Fee Rates Accurately

Issued on  | Posted on  | Report number: A-05-17-00040

The Prescription Drug User Fee Act (PDUFA) of 1992, P.L. No. 102-571, authorized the Food and Drug Administration (FDA) to collect prescription drug user fees from pharmaceutical and biotechnology companies seeking FDA approval of certain human drug and biological products to expedite the review of human drug applications. Congress must reauthorize the PDUFA every 5 years; it was renewed in 1997, 2002, 2007, 2012, and 2017. FDA expects to use the prescription drug user fees it collects under the PDUFA to meet its goals for the timely review of human drug applications. We performed this audit to determine whether FDA accurately computed prescription drug user fee rates.

Click to Translate text before this point Start of
Translation
Our objective was to determine whether FDA accurately computed prescription drug user fee rates.

We obtained and reviewed documentation from the FDA, such as policies and procedures and financial records, to determine whether it accurately computed prescription drug user fee rates. We also analyze prescription drug user fee collection amounts. We limited our review to $821.9 million in prescription drug user fee collections reported for October 1, 2014, through September 30, 2015.

FDA computed prescription drug user fee rates accurately. We determined that the human drug review workload computation was appropriate. We as determined that the inflation adjustment for personnel compensation and benefits and nonpersonnel compensation and benefits costs were correctly computed.

Accordingly, this report contains no recommendations.


-
-
-